Combinatorial approach to N-substituted aminocyclitol libraries by solution-phase parallel synthesis and preliminary evaluation as glucocerebrosidase inhibitors

Journal of Combinatorial Chemistry

Volumn 9, Issue 1, 2007, Pages 43-52

  Serrano, Pedro ^a,b   Casas, Josefina ^a   Zucco, Martine ^c   Emeric, Gilbert ^c   Egido Gabás, Meritxell ^a   Llebaria, Amadeu ^a   Delgado, Antonio ^a,b  

^a DEPARTMENT OF ENVIRONMENTAL CHEMISTRY   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c BAYER CROPSCIENCE AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL DERIVATIVE; CARBAMIC ACID DERIVATIVE; CYCLOHEXANE DERIVATIVE; DRUG DERIVATIVE; ENZYME INHIBITOR; GLUCOSYLCERAMIDASE; HEXOSAMINE; IMIGLUCERASE; SULFONAMIDE; UREA;

ARTICLE; COMBINATORIAL CHEMISTRY; DRUG ANTAGONISM; HUMAN; IC 50; INFRARED SPECTROPHOTOMETRY; MASS SPECTROMETRY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; SYNTHESIS;

ALCOHOLS; CARBAMATES; COMBINATORIAL CHEMISTRY TECHNIQUES; CYCLOHEXANES; ENZYME INHIBITORS; GLUCOSYLCERAMIDASE; HEXOSAMINES; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MASS SPECTROMETRY; SPECTROPHOTOMETRY, INFRARED; SULFONAMIDES; UREA;

EID: 33846649594     PISSN: 15204766     EISSN: None     Source Type: Journal    
DOI: 10.1021/cc060080o     Document Type: Article

References (30)

1. Mahmud, T. Nat. Prod. Rep. 2003, 20, 137-166.
2. Chapleur, Y. Carbohydrate Mimics; Wiley-VCH: Weinheim, 1998.
3. See inter-alia: (a) Ogawa, S.; Fujieda, S.; Sakata, Y.; Ishizaki, M.; Hisamatsu, S.; Okazaki, K. Bioorg. Med. Chem. Lett. 2003, 13, 3461-3463.
4. (b) Tanaka, K. S.; Winters, G. C.; Batchelor, R. J.; Einstein, F. W.; Bennet, A. J. J. Am. Chem. Soc. 2001, 123, 998-999.
5. (c) Gravier-Pelletier, C.; Maton, W.; Dintinger, T.; Tellier, C.; Le Mener, Y. Tetrahedron 2003, 59, 8705-8720 and references therein.
6. Jana, S.; Deb, J. K. Curr. Drug Targets 2005, 6, 353-361.
7. Ogawa, S. Carbohydrates in Drug Design; Dekker: New York, 1997; pp 433-469.
8. Zheng, Y. G.; Shentu, X. P.; Shen, Y. C. J. Enzyme Inhib. Med. Chem. 2005, 20, 49-53.
9. For recent examples of inositol derivatives as enzyme inhibitors, see: (a) Bashir-Uddin, Surfraz, M.; Miller, D. J.; Gani, D.; Allemann, R. K. Tetrahedron Lett. 2003, 44, 7677-7679.
10. (b) Mills, S. J.; Potter, B. V. L. Bioorg. Med. Chem. 2003, 11, 4245-4253.
11. (c) Mills, S. J.; Backers, K.; Erneux, C.; Potter, B. Org. Biomol. Chem. 2003, 1, 3546-3556.
12. (d) Chang, Y.; Choi, G.; Bae, Y.; Burdett, M.; Moon, H.; Lee, J.; Gray, N.; Schultz, P.; Meijer, L.; Chung, S.; Choi, K.; Suh, P.; Ryu, S. ChemBioChem 2002, 3, 897-901.
13. (e) Ahn, Y.; Chung, S. Bull. Korean Chem. Soc. 2002, 23, 515-517.
14. (a) Clarke, J. H. Curr. Biol. 2003, 13, R815-7.
15. (b) Brunn, G.; Fauq, A. H.; Chow, S.; Kozikowski, A. P.; Gallegos, A.; Powis, G. Cancer Chemother. Pharmacol. 1994, 35, 71-79.
16. (c) Panayotou, G.; Waterfield, M. D.; Clarke, J. H. Trends Cell Biol. 1992, 2, 358-60.
17. (d) Powis, G.; Aksoy, I. A.; Melder, D. C.; Aksoy, S.; Eichinger, H.; Fauq, A. H.; Kozikowski, A. P. Cancer Chemother. Pharmacol. 1991, 29, 95-104.
18. Serrano, P.; Llebaria, A.; Delgado, A. J. Org. Chem. 2005, 70, 7829-7840.
19. Egido-Gabas, M.; Serrano, P.; Casas, J.; Llebaria, A.; Delgado, A. Org. Biomol. Chem. 2005, 3, 1195-1201.
20. Inositols of the chiro series 2 were obtained as racemic mixtures.
21. Nowick, J. S.; Holmes, D. L.; Noronha, G.; Smith, E. M.; Nguyen, T. M.; Huang, S. L. J. Org. Chem. 1996, 61, 3929-3934.
22. Building blocks were selected from among the several thousands of commercially available and "in-house" synthesized possibilities by generating a virtual library. The library thus obtained was filtered to remove incompatibilities with the proposed reaction pathway and classified into different families according to structural criteria. Each family was further filtered according to modified Lipinski's rules. (Tice, C. M. Pest. Manage. Sci. 2001, 57, 3-16.) Final building block selection was made by hand on the basis of structural diversity and commercial availability.
23. Borch, R. F.; Bernstein, M. D.; Brurst, H. D. J. Am. Chem. Soc. 1971, 93, 2897-2904.
24. Manescalchi, F.; Nardi, A. R.; Savoia, D. Tetrahedron Lett. 1994, 35, 2775-2778.
25. Sim, M. M.; Lee, C. L.; Ganesan, A. J. Org. Chem. 1997, 62, 9358-9360.
26. Rademann, J.; Meldal, M.; Bock, K. Chem. Eur. J. 1999, 5, 1218-1225.
27. The main limitation was the impossibility to avoid hydrogen losses in the standard 96-well plate format used.
28. Only library members of purity higher than 70%, according to HPLC-ELS-MS, were submitted to enzyme inhibition studies (see Supporting Information for further details).
29. Premkumar, L.; Sawkar, A. R.; Boldin-Adamsky, S.; Toker, L.; Silman, I.; Kelly, J. W.; Futerman, A. H.; Sussman, J. L. J. Biol. Chem. 2005, 280, 23815-23819.
30. Futerman, A. H.; Sussman, J. L.; Horowitz, M.; Silman, I.; Zimran, A. Trends Pharmacol. Sci. 2004, 25, 147-151.